In This Article:
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Heron Therapeutics, Inc.'s (NASDAQ:HRTX) case, it's fantastic news for shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Check out our latest analysis for Heron Therapeutics
The Last 12 Months Of Insider Transactions At Heron Therapeutics
Over the last year, we can see that the biggest insider purchase was by CEO & Director Craig Collard for US$138k worth of shares, at about US$0.92 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$1.78. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
Heron Therapeutics insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Heron Therapeutics
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Heron Therapeutics insiders own 1.0% of the company, worth about US$2.7m. We consider this fairly low insider ownership.
So What Does This Data Suggest About Heron Therapeutics Insiders?
The fact that there have been no Heron Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Heron Therapeutics stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Heron Therapeutics. For instance, we've identified 3 warning signs for Heron Therapeutics (1 shouldn't be ignored) you should be aware of.
But note: Heron Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.